Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for ...

While the immediate post- ChatGPT era was all about chasing OpenAI, the current situation for AI firms is more conventionally ...

A software engineer at Google sparked an online debate after admitting he doesn’t understand fundamental coding concepts ...

There's no bound for thinking, no final horizon. We will likely always prefer by a lot the model that’s only smarter by a ...

Navitas Corporation (NASDAQ: NVTS) specializes in gallium nitride power systems that enable more efficient AI hardware ...

On February 11, 2025, the current US government published a website of the US Senate Commerce Committee (Chairman Ted Cruz) announcing the results of an “investigation” into research grants funded by ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

Earlier this month, the Trump administration directed the National Institutes of Health (NIH) to impose limits on specific ...

This little-known artificial intelligence growth stock is backed by chipmaker Nvidia and recently jumped nearly 24% in a ...

Diplomats rely on information to shape major negotiations like the emerging talks around ending the war in Ukraine and major ...